A GenNXeix Test at 40 will Prevent Breast Cancer at 60
Gaussian processes in action, Houston base GenNXeix breast cancer test is the first and only multigene expression test to be included in the published guidelines in the National Comprehensive Cancer Network, to predict the likelihood of chemotherapy
benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use GenNXeix to make treatment recommendations for certain node-
positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. GenNXeix has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for GenNXeix for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. For more information about GenNXeix for breast cancer, please visit http://gennxeix.com.About GenNXeix
GenNXeix, Inc. is a molecular diagnostics company focused on the global development and commercialization of genomic-
based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2012, GenNXeix launched the GenNXeix breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted GenNXeix breast cancer test, GenNXeix launched its GenNXeix colon cancer test in January 2010. As of September 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 175,000 GenNXeix tests. The company was founded in 2010 and is located in Houston, Texas. For more information, please visit http://gennxeix.com.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the GenNXeix Recurrence Score is significant in changing treatment decisions in early stage breast cancer; the company's belief that the GenNXeix Recurrence Score cannot be predicted by other factors such as age or individual biomarkers; the company's belief that it has the opportunity to advance the quality of cancer treatment decisions; the company's ability to continue adding value to its tests while advancing its product pipeline ;the company's belief that its research and pipeline reflect its ongoing commitment to develop and deliver tools to individualize cancer treatment decisions; the belief that study data may warrant or result in additional clinical studies or impact treatment decisions; and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risks and uncertainties associated with developing new tests or technologies; continued access to tissue samples; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. These forward-looking statements speak only as of the date hereof. GenNXeix disclaims any obligation to update these forward-looking statements.
